Is 200 Grams of Protein Too Much on TRT? (TRT Q&As)
Timeline
Timestamp
Topic
00:20
Can you review my blood work after four years on TRT?
A 47-year-old member taking 125 mg of testosterone weekly asks Dr. O’Connor to review his latest labs after noticing changes in testosterone, hemoglobin, and hematocrit. Dr. O’Connor works through the ABCDs™ and identifies his elevated BUN and roughly 200-gram daily protein intake as an important area to address while reviewing his overall metabolic, kidney, cardiovascular, and TRT markers.
A 47-year-old member taking 125 mg of testosterone weekly asks Dr. O’Connor to review his latest labs after noticing changes in testosterone, hemoglobin, and hematocrit. Dr. O’Connor works through the ABCDs™ and identifies his elevated BUN and roughly 200-gram daily protein intake as an important area to address while reviewing his overall metabolic, kidney, cardiovascular, and TRT markers.
21:00
Should I get an advanced lipid panel that measures LDL particle size?
Dr. O’Connor explains that advanced lipid testing can provide additional cardiovascular information, including particle-related measurements, ApoB, and Lp(a). He places those results in the larger context of family history and coronary imaging rather than relying only on a standard LDL cholesterol value.
Dr. O’Connor explains that advanced lipid testing can provide additional cardiovascular information, including particle-related measurements, ApoB, and Lp(a). He places those results in the larger context of family history and coronary imaging rather than relying only on a standard LDL cholesterol value.
29:50
Why did my testosterone level rise after I lowered my weekly TRT dose?
The member says he reduced testosterone to 125 mg per week split into two doses, yet his total and free testosterone increased while SHBG fell and hemoglobin and hematocrit improved. Dr. O’Connor explains that testosterone laboratory values can fluctuate and emphasizes interpreting them alongside symptoms and the more important ABCDs™ health markers rather than chasing a single testosterone number.
The member says he reduced testosterone to 125 mg per week split into two doses, yet his total and free testosterone increased while SHBG fell and hemoglobin and hematocrit improved. Dr. O’Connor explains that testosterone laboratory values can fluctuate and emphasizes interpreting them alongside symptoms and the more important ABCDs™ health markers rather than chasing a single testosterone number.
41:40
Can you review my blood work after I recently started TRT?
A 49-year-old man who recently began 100 mg of testosterone per week asks Dr. O’Connor to review his labs in the setting of low testosterone, difficulty gaining weight, and worsening sleep. Dr. O’Connor reviews his metabolic and cardiovascular markers and identifies concerns including borderline glycemic control and elevated ferritin that warrant additional attention and follow-up.
A 49-year-old man who recently began 100 mg of testosterone per week asks Dr. O’Connor to review his labs in the setting of low testosterone, difficulty gaining weight, and worsening sleep. Dr. O’Connor reviews his metabolic and cardiovascular markers and identifies concerns including borderline glycemic control and elevated ferritin that warrant additional attention and follow-up.
55:00
If I’m taking retatrutide, does it take the place of metformin?
Dr. O’Connor explains that retatrutide and metformin work differently and discusses the potential metabolic effects of the GLP-1/GIP/glucagon triple agonist. After reviewing the member’s fasting glucose and A1C, however, he says the member’s current metabolic numbers do not indicate that he needs metformin.
Dr. O’Connor explains that retatrutide and metformin work differently and discusses the potential metabolic effects of the GLP-1/GIP/glucagon triple agonist. After reviewing the member’s fasting glucose and A1C, however, he says the member’s current metabolic numbers do not indicate that he needs metformin.
60:00
Is one gram of protein per pound of body weight still a good daily target?
Dr. O’Connor says he does not favor automatically using one gram per pound and instead discusses protein intake in grams per kilogram of body weight. He emphasizes avoiding chronically excessive intake, particularly when BUN is elevated or kidney health is a concern, and individualizing protein needs according to health, age, training, and goals.
Dr. O’Connor says he does not favor automatically using one gram per pound and instead discusses protein intake in grams per kilogram of body weight. He emphasizes avoiding chronically excessive intake, particularly when BUN is elevated or kidney health is a concern, and individualizing protein needs according to health, age, training, and goals.
Video Summary
The discussion focuses on practical testosterone therapy management, including how symptoms align with laboratory trends rather than isolated results. Attention is given to dosing consistency and monitoring intervals to avoid unnecessary variability. Clinical judgment is emphasized over reactive changes.
A central portion addresses lab interpretation, including markers that reflect hematologic and cardiometabolic risk. The episode explains why contextual factors must be considered before intervention. Risk mitigation strategies are framed as part of routine follow-up.
The closing segment integrates testosterone therapy within broader preventive care. Long-term safety, ongoing monitoring, and individualized adjustment are reinforced. Hormone therapy is positioned as one component of comprehensive clinical oversight.
Drug Callouts
Drug
Description
Testosterone
Testosterone is an androgen hormone used therapeutically to treat confirmed testosterone deficiency and related symptoms. In this episode, testosterone therapy is discussed as a treatment requiring consistent dosing, lab monitoring, and risk-aware decision-making.
Condition Callouts
Condition
Description
Polycythemia
Polycythemia is an increase in red blood cell mass that can raise blood viscosity and cardiovascular risk. It is discussed in relation to monitoring hematologic markers during testosterone therapy.
Key Takeaways
- Testosterone therapy decisions should be guided by both symptoms and laboratory trends.
- Consistency in dosing and monitoring improves interpretability of results.
- Certain lab changes require context before intervention.
- Hematologic and cardiovascular risks must be monitored during therapy.
- Long-term safety depends on individualized, data-driven management.